Thea K. Våtsveen

  • Postdoc; PhD
 

Publications 2021

Oksvold MP, Berglund UW, Gad H, Bai B, Stokke T, Rein ID, Pham T, Sanjiv K, Øy GF, Norum JH, Smeland EB, Myklebust JH, Helleday T, Våtsveen TK (2021)
Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
Sci Rep, 11 (1), 6317
DOI 10.1038/s41598-021-85613-8, PubMed 33737576

Sanjiv K, Calderón-Montaño JM, Pham TM, Erkers T, Tsuber V, Almlöf I, Höglund A, Heshmati Y, Seashore-Ludlow B, Nagesh Danda A, Gad H, Wiita E, Göktürk C, Rasti A, Friedrich S, Centio A, Estruch M, Våtsveen TK, Struyf N, Visnes T, Scobie M, Koolmeister T, Henriksson M, Wallner O, Sandvall T et al. (2021)
MTH1 inhibitor TH1579 induces oxidative DNA damage and mitotic arrest in acute myeloid leukemia
Cancer Res (in press)
DOI 10.1158/0008-5472.CAN-21-0061, PubMed 34593524

Publications 2018

Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP (2018)
Artesunate shows potent anti-tumor activity in B-cell lymphoma
J Hematol Oncol, 11 (1), 23
DOI 10.1186/s13045-018-0561-0, PubMed 29458389

Publications 2016

Vandsemb EN, Bertilsson H, Abdollahi P, Størkersen Ø, Våtsveen TK, Rye MB, Rø TB, Børset M, Slørdahl TS (2016)
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration
J Transl Med, 14, 71
DOI 10.1186/s12967-016-0830-z, PubMed 26975394

Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T (2016)
VOLIN and KJON-Two novel hyperdiploid myeloma cell lines
Genes Chromosomes Cancer, 55 (11), 890-901
DOI 10.1002/gcc.22388, PubMed 27311012

Våtsveen TK, Sponaas AM, Tian E, Zhang Q, Misund K, Sundan A, Børset M, Waage A, Brede G (2016)
Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro
J Hematol Oncol, 9 (1), 75
DOI 10.1186/s13045-016-0306-x, PubMed 27581518

Publications 2015

Nahi H, Våtsveen TK, Lund J, Heeg BM, Preiss B, Alici E, Møller MB, Wader KF, Møller HE, Grøseth LA, Østergaard B, Dai HY, Holmberg E, Gahrton G, Waage A, Abildgaard N (2015)
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21
Eur J Haematol, 96 (1), 46-54
DOI 10.1111/ejh.12546, PubMed 25779478

Tian E, Børset M, Sawyer JR, Brede G, Våtsveen TK, Hov H, Waage A, Barlogie B, Shaughnessy JD, Epstein J, Sundan A (2015)
Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression
Genes Chromosomes Cancer, 54 (11), 692-701
DOI 10.1002/gcc.22280, PubMed 26220195

Publications 2014

Olsen OE, Wader KF, Misund K, Våtsveen TK, Rø TB, Mylin AK, Turesson I, Størdal BF, Moen SH, Standal T, Waage A, Sundan A, Holien T (2014)
Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin
Blood Cancer J, 4, e196
DOI 10.1038/bcj.2014.16, PubMed 24658374

Rampa C, Tian E, Våtsveen TK, Buene G, Slørdahl TS, Børset M, Waage A, Sundan A (2014)
Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients
Biomark Res, 2 (1), 8
DOI 10.1186/2050-7771-2-8, PubMed 24716444

Publications 2013

Müller R, Misund K, Holien T, Bachke S, Gilljam KM, Våtsveen TK, Rø TB, Bellacchio E, Sundan A, Otterlei M (2013)
Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells
PLoS One, 8 (7), e70430
DOI 10.1371/journal.pone.0070430, PubMed 23936203

Publications 2012

Holien T, Våtsveen TK, Hella H, Waage A, Sundan A (2012)
Addiction to c-MYC in multiple myeloma
Blood, 120 (12), 2450-3
DOI 10.1182/blood-2011-08-371567, PubMed 22806891

Publications 2011

Holien T, Våtsveen TK, Hella H, Rampa C, Brede G, Grøseth LA, Rekvig M, Børset M, Standal T, Waage A, Sundan A (2011)
Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC
Leukemia, 26 (5), 1073-80
DOI 10.1038/leu.2011.263, PubMed 21941367

Publications 2009

Brenne AT, Fagerli UM, Shaughnessy JD, Våtsveen TK, Rø TB, Hella H, Zhan F, Barlogie B, Sundan A, Børset M, Waage A (2009)
High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis
Eur J Haematol, 82 (5), 354-63
DOI 10.1111/j.1600-0609.2009.01225.x, PubMed 19191868

Hov H, Tian E, Holien T, Holt RU, Våtsveen TK, Fagerli UM, Waage A, Børset M, Sundan A (2009)
c-Met signaling promotes IL-6-induced myeloma cell proliferation
Eur J Haematol, 82 (4), 277-87
DOI 10.1111/j.1600-0609.2009.01212.x, PubMed 19187270

Våtsveen TK, Brenne AT, Dai HY, Waage A, Sundan A, Børset M (2009)
FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14)
Eur J Haematol, 83 (5), 471-6
DOI 10.1111/j.1600-0609.2009.01312.x, PubMed 19594619

Våtsveen TK, Tian E, Kresse SH, Meza-Zepeda LA, Gabrea A, Glebov O, Dai HY, Sundan A, Kuehl WM, Børset M (2009)
OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus
Leuk Res, 33 (12), 1670-7
DOI 10.1016/j.leukres.2009.03.001, PubMed 19395026

Publications 2007

Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, Shaughnessy JD, Sundan A, Børset M (2007)
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells
Blood, 111 (2), 806-15
DOI 10.1182/blood-2007-07-101139, PubMed 17934070

Page visits: 4390